Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Censoring Survival Data01:09

Censoring Survival Data

96
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
96
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

146
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
146
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

131
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
131
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

239
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
239
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

438
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
438

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation.

Annals of internal medicine·2026
Same author

Evaluating Associations Between Cumulative Use of Chronic Liver Injury-Inducing Antiretroviral Therapy and Hepatocellular Carcinoma, By Chronic Liver Disease Status.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Racial, Ethnic, and Neighborhood Disparities in Acute Kidney Injury in Pediatric Acute Leukemia.

Cancer medicine·2026
Same author

Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.

Blood advances·2026
Same author

Bayesian shrinkage priors for penalized synthetic control estimators in the presence of spillovers.

Biometrics·2026
Same author

Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative Groups.

JCO clinical cancer informatics·2026

Related Experiment Video

Updated: Jul 5, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K

Bayesian semiparametric model for sequential treatment decisions with informative timing.

Arman Oganisian1, Kelly D Getz2, Todd A Alonzo3

  • 1Department of Biostatistics, Brown University, Providence, RI, United States.

Biostatistics (Oxford, England)
|January 17, 2024
PubMed
Summary

This study introduces a Bayesian model to assess dynamic treatment strategies for pediatric acute myeloid leukemia (AML), considering anthracyclines (ACT) and patient recovery times to estimate survival probabilities.

Keywords:
bayesian inferencecausal inferencedynamic treatment regimessurvival analysis

More Related Videos

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.4K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Related Experiment Videos

Last Updated: Jul 5, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.4K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Pediatric Oncology

Background:

  • Dynamic treatment rules are crucial for optimizing pediatric acute myeloid leukemia (AML) therapy.
  • Anthracyclines (ACT) are effective AML treatments but pose cardiotoxicity risks, complicating treatment decisions.
  • Time-varying confounding and patient dropout present significant challenges in analyzing treatment impacts.

Purpose of the Study:

  • To develop a statistical model for estimating survival probabilities under dynamic treatment strategies in pediatric AML.
  • To address confounding, informative timing, and patient dropout in treatment efficacy analysis.
  • To evaluate hypothetical dynamic treatment rules for anthracyclines (ACT) based on evolving patient conditions.

Main Methods:

  • A generative Bayesian semiparametric model utilizing Gamma Process priors was developed.
  • The model captures continuous-time transitions between treatment courses, death, or dropout.
  • G-computation was employed to adjust for time-varying confounding and estimate survival probabilities.

Main Results:

  • The model successfully estimated survival probabilities under dynamic anthracycline (ACT) treatment strategies.
  • Adjusted survival estimates accounted for time-varying confounding and patient recovery times.
  • The approach allows for the evaluation of hypothetical treatment modifications based on cardiac function.

Conclusions:

  • The developed Bayesian semiparametric model provides a robust framework for analyzing dynamic treatment rules in pediatric AML.
  • This method enables personalized treatment strategies by dynamically adjusting anthracycline (ACT) use.
  • Accurate survival estimation is crucial for improving outcomes in pediatric cancer patients undergoing complex treatment regimens.